Literature DB >> 11996414

Management of Helicobacter pylori infection.

Linda N Meurer1, Douglas J Bower.   

Abstract

Helicobacter pylori is the cause of most peptic ulcer disease and a primary risk factor for gastric cancer. Eradication of the organism results in ulcer healing and reduces the risk of ulcer recurrence and complications. Testing and treatment have no clear value in patients with documented nonulcer dyspepsia; however, a test-and-treat strategy is recommended but for patients with undifferentiated dyspepsia who have not undergone endoscopy. In the office setting, initial serology testing is practical and affordable, with endoscopy reserved for use in patients with alarm symptoms for ulcer complications or cancer, or those who do not respond to treatment. Treatment involves 10- to 14-day multidrug regimens including antibiotics and acid suppressants, combined with education about avoidance of other ulcer-causing factors and the need for close follow-up. Follow-up testing (i.e., urea breath or stool antigen test) is recommended for patients who do not respond to therapy or those with a history of ulcer complications or cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11996414

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  8 in total

Review 1.  Safety of 14C-UBT for diagnosis of Helicobacter pylori infection in pregnancy.

Authors:  Yedidia Bentur; Doreen Matsui; Gideon Koren
Journal:  Can Fam Physician       Date:  2009-05       Impact factor: 3.275

2.  Presence and density of Helicobacter pylori biofilms in human gastric mucosa in patients with peptic ulcer disease.

Authors:  James M Coticchia; Choichi Sugawa; Vivian R Tran; Jose Gurrola; Evan Kowalski; Michael A Carron
Journal:  J Gastrointest Surg       Date:  2006-06       Impact factor: 3.452

3.  The alcohol dehydrogenase isoenzyme alcohol dehydrogenase IV as a candidate marker of Helicobacter pylori infection.

Authors:  Wojciech Jelski; Magdalena Laniewska-Dunaj; Anna Strumnik; Maciej Szmitkowski
Journal:  Arch Med Sci       Date:  2014-10-23       Impact factor: 3.318

4.  Structure based annotation of Helicobacter pylori strain 26695 proteome.

Authors:  Swati Singh; Praveen Kumar Guttula; Lalitha Guruprasad
Journal:  PLoS One       Date:  2014-12-30       Impact factor: 3.240

5.  Relationship of Halitosis with Gastric Helicobacter Pylori Infection.

Authors:  Farnaz HajiFattahi; Maryam Hesari; Homayoun Zojaji; Fatemeh Sarlati
Journal:  J Dent (Tehran)       Date:  2015-03

6.  Protective Effects of Silibinin on Helicobacter pylori-induced Gastritis: NF-κB and STAT3 as Potential Targets.

Authors:  Kyunghwa Cho; Hee Geum Lee; Juan-Yu Piao; Su-Jung Kim; Hye-Kyung Na; Young-Joon Surh
Journal:  J Cancer Prev       Date:  2021-06-30

7.  Dual drug delivery system for targeting H. pylori in the stomach: preparation and in vitro characterization of amoxicillin-loaded Carbopol® nanospheres.

Authors:  Sree Harsha
Journal:  Int J Nanomedicine       Date:  2012-09-04

8.  In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori.

Authors:  Morris O Makobongo; Leo Einck; Richard M Peek; D Scott Merrell
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.